Single-dose liposomal amphotericin B (AmBisome<sup>®</sup>) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial

Single-dose liposomal amphotericin B (AmBisome<sup>®</sup>) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial

<p>Abstract</p> <p>Background</p> <p>AmBisome<sup>® </sup>is an efficacious, safe anti-leishmanial treatment. There is growing interest in its use, either as a single dose or in combination treatments. In East Africa, the minimum optimal single-dosage has no...

Full description

Bibliographic Details
Main Authors: Smith Peter G, Wasunna Monique, Musa Ahmed, Musa Brima, Yifru Sisay, Khalil Eltahir AG, Omollo Raymond, Edwards Tansy, Royce Catherine, Ellis Sally, Balasegaram Manica, Hailu Asrat
Format: Article
Language:English
Published: BMC 2011-03-01
Series:Trials
Online Access:http://www.trialsjournal.com/content/12/1/66

Internet

http://www.trialsjournal.com/content/12/1/66

Similar Items